A Novel Metabolic Disease Research Model - The Wild Mouse 750
In recent decades, the prevalence of metabolic disorders such as obesity, diabetes, NAFLD, and cardiovascular diseases has continued to rise. Patients with obesity and diabetes mellitus frequently have multiple disease phenotypes, including abnormal lipid metabolism, impaired liver function, and even damage to the heart and kidneys.Animal models that effectively simulate human metabolic disease phenotypes are critical in studying disease mechanisms and evaluating therapeutic drugs.
Based on previous research, wild mice can be used to introduce genetic variation into inbred mouse strains. By using continuous backcrossing between inbred strains and wild mice, a new inbred strain can be created that differs in only one chromosome from the recipient strain (original inbred strain). The introduction of genetic variations by consomic strains brings convenience in the identification of genes related to complex traits, and provides new resources to discover novel signaling pathways and disease mechanisms.
GemPharmatech has created a new strain, Wild Mouse 750, by transferring chromosome 1 from a wild mouse to the C57BL/6JGpt inbred strain. The mouse strain (Official Full Name: B6-Chr1YP1, Strain Number: D000750) is susceptible to metabolic disorders.
At 26 weeks, Wild Mouse 750 and B6J mice exhibit distinct tissue adiposity. The 750 mice show significantly more adipose tissue than B6J mice in all depots. Mesenteric (m), subcutaneous (s), epididymal (e), white adipose (WAT), brown adipose tissue (BAT).
Our 750 mice exhibit a severe spontaneous obese phenotype after 8 weeks of age. Characteristics of the obese phenotype include significantly elevated insulin and cholesterol levels and mildly impaired glucose tolerance. With increased age, 750 mice develop a fatty liver phenotype. The spontaneous obese phenotype in 750 mice mimics the development of obesity in humans. This new strain can be used to identify new pathogenic mechanisms, and evaluate the safety and efficacy of weight-loss, lipid-lowering, and fatty liver alleviation drugs.
Recommended by LinkedIn
After 8 weeks, the body weight and cholesterol levels of 750 mice increased gradually, and at 9 weeks, leptin and insulin levels were significantly higher than these in B6J control mice.
GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and preclinical services to global R&D communities.
Email: lisy2@gempharmatech.com
leah.li@gempharmatech.com
Tell: +86 17751038661